

## **Opportunities in Non-Surgical Bio-Implants: Injectable Biomaterials, Applications, and Leading Players**

The report details the major players, market opportunities, and emerging sectors that are changing the landscape of injectable treatments and major applications in cosmetic dermatology and orthopedics. It provides insights into potential high-growth prospects for novel subcutaneous, intradermal, and intra-articular products, as well as novel matrix formulations for tissue and bone regeneration.

### **Scope**

- Analysis of current biomaterials that have been developed as injectable medical devices.
- Evaluation of the barriers and issues associated with biocompatibility of developed biomaterial types.
- Current trends in injectable bio-implants for aesthetic/medical indications and the companies involved.
- Evaluation of novel technologies that may change the landscape of current treatments.
- Identification of leading players and benchmarking of key products against others.

### **Research and analysis highlights**

Biocompatibility is a critical issue that challenges research and development of injectable bio-implants. Commercialized products are limited to collagens, hyaluronic acids, polymer formulations, and ceramics.

Commercial opportunities are evident for approved viscoaugmentation and viscosupplementation products in crossover fields where injectable bio-implants may be developed for a variety of diverse conditions.

Companies are increasingly licensing and re-marketing products across therapeutic areas to maximize sales revenues, novelty, and product choice.

### **Key reasons to purchase this research**

- Gain understanding of the key obstacles in research for biocompatibility in the development of injectable medical devices
- Evaluates the key recent developments and activities of companies who are developing and licensing injectable bio-implant technologies
- Identifies trends in product development and the strategies employed to enhance product lines and improve profitability
- Provides analyses of research themes and comments on pipeline products that may offer alternatives to existing licensed products
- Enables rapid assessment of current and pipeline products that may impact proprietary sales and product development

# Table of Contents

Opportunities in Non-surgical Bio-implants Executive summary	10
Injectable biomaterials	10
Viscoaugmentation	11
Viscosupplementation	12
Alloplastic injectable biomaterials: R&D	13
Chapter 1 Injectable biomaterials	16
Summary	16
Introduction	17
Development issues	18
Problems with biocompatibility	18
Design factors	20
Rationale for development of injectable biomaterials	22
Types of injectable biomaterials	22
Collagen	23
Hyaluronic acid	24
Hydrogels	25
Hydroxyapatite	26
Calcium phosphate ceramic pastes	27
Biopolymers	27
Adverse reactions associated with current injectable biomaterials	28
Ideal properties of injectable biomaterials	29
Chapter 2 Viscoaugmentation	32
Summary	32
Soft tissue viscoaugmentation bio-implants	33
Trends in injectable cosmetic treatments in the US	33
Primary indications for soft-tissue augmentation products	34
Collagen	35
Companies, products, and market activities	36
Allergan's Zyderm-Zyplast/Cosmoderm-Cosmoplast range	36
Recent industry activities: Evolence discontinued	37
Hyaluronic acid	38
Companies, products, and market activities	39
Adoderm	39
Allergan	39
Anteis	41
Anika Therapeutics	42
BioPolymer GmbH & Co. KG	43
Coapt Systems	45
Fidia Farmaceutici	46
KuhraVital Dermapharma	46
Laboratoires Filorga	46
L&M Aesthetic Equipment/Parpas Group	47
LCA Pharmaceutical	47
Hangzhou Gallop Biological Products	48

Novatex Bioengineering/Laboratoires Orgév 49  
Johnson & Johnson/Mentor Corp. 50  
Puragen 50  
Merz Pharma/Merz Aesthetics 51  
Q-Med 52  
Nordic Aesthetics 54  
Prollenium Medical Technologies 55  
Rofil Medical/Philoderm Aesthetics 56  
Teoxane Laboratoires 56  
Biopolymers 57  
Dimethicone/silicone oil 57  
Companies, products, and market activities 58  
Contura International 58  
FzioMed 60  
Polymekon 60  
Suneva 61  
ProCytech 62  
Sanofi-Aventis 63  
Generic polymeric soft tissue fillers 63  
Ceramics/hybrid technologies 64  
Companies, products, and market activities 64  
BioForm Medical 64  
Stiefel Laboratories/GlaxoSmithKline 65  
Chapter 3 Viscosupplementation 68  
Summary 68  
Intra-articular injectable bio-implants 69  
Marketed injectable products and company activities 70  
Anika Therapeutics 70  
Anteis 71  
BioPolymer 71  
Curasan 72  
Ferring Pharmaceuticals 72  
Fidia Farmaceutici 73  
Genzyme Corp 73  
LCA Pharmaceutical 74  
Novatex Bioengineering 75  
Ortho Biotech/Johnson & Johnson/Anika Therapeutics 76  
Q-Med/Smith & Nephew 76  
Sanofi-Aventis 77  
Seikagaku/Smith & Nephew 77  
TRB Chemedica 78  
Generic sodium hyaluronate 79  
Chapter 4 Alloplastic injectable biomaterials: R&D 82  
Summary 82  
Alloplastic injectable biomaterials: current R&D 83  
Viscoaugmentation: cosmetic applications 83  
Albiorex 83  
FibroGen 84

Kythera Pharmaceuticals 84  
Moma Therapeutics 84  
Novatex Bioengineering 85  
Prollenium Medical Technologies 85  
Viscosupplementation: medical/surgical applications 85  
Anika Therapeutics 86  
Barrow Neurological Institute at St. Joseph's Hospital and Medical Center, US 86  
Biotechnology Institute IMASD 87  
Genzyme Corp 87  
Pioneer Surgical Technology 87  
Prollenium Medical Technologies 88  
Seikagaku 88  
Considerations, insights, and recommendations 89  
Appendix 91  
Scope 91  
Methodology 91  
Glossary 92  
Index 94

### **List of Figures**

Figure 1.1: Potential adverse responses to implanted biomaterials 19  
Figure 1.2: Essential design components for biocompatibility of implantable biomaterials 20  
Figure 1.3: Types of marketed injectable biomaterials 23  
Figure 1.4: Medical applications and benefits of hydrogels 26  
Figure 1.5: Potential adverse reactions associated with injectable biomaterials 29  
Figure 2.6: Trends in injectable treatments in the US, 2003–2009 34  
Figure 2.7: Primary indications for soft tissue dermal fillers 35

### **List of Tables**

Table 1.1: Basic properties and medical applications of biomaterials 18  
Table 1.2: Medical applications of hyaluronic acid 25  
Table 1.3: Medical applications of biopolymers 28  
Table 2.4: Marketed collagen-based injectable products 36  
Table 2.5: Main indications for Allergan's collagen-based injectable products 37  
Table 2.6: Adoderm's hyaluronic acid-based injectable products 39  
Table 2.7: Allergan's hyaluronic acid-based injectable products 41  
Table 2.8: Anteis' hyaluronic acid-based injectable products 42  
Table 2.9: Anika Therapeutics' hyaluronic acid-based injectable products 43  
Table 2.10: Biopolymer's marketed hyaluronic acid-based injectable products 44  
Table 2.11: Coapt Systems' marketed hyaluronic acid-based injectable products 45  
Table 2.12: KuhraVital's marketed hyaluronic acid-based injectable products 46  
Table 2.13: Laboratoires Filorga's marketed hyaluronic acid-based injectable products 47  
Table 2.14: L&M Aesthetic's marketed hyaluronic acid-based injectable products 47  
Table 2.15: LCA Pharma's marketed hyaluronic acid-based injectable products 48  
Table 2.16: HGBP's marketed hyaluronic acid-based injectable products 49  
Table 2.17: Novatex's hyaluronic acid-based injectable products 50  
Table 2.18: J&J's marketed hyaluronic acid-based injectable products 50

Table 2.19: Merz Pharma's marketed hyaluronic acid-based injectable products	51
Table 2.20: Q-Med's marketed hyaluronic acid-based injectable products	52
Table 2.21: Nordic Aesthetics' marketed hyaluronic acid-based injectable products	54
Table 2.22: Prollenium's marketed hyaluronic acid-based injectable products	55
Table 2.23: Rofil Medical/Philiderm Aesthetics' marketed hyaluronic acid-based injectable products	56
Table 2.24: Teoxane's marketed hyaluronic acid-based injectable products	57
Table 2.25: Contura's marketed polymer-based injectable products	59
Table 2.26: FzioMed's marketed polymer-based injectable products	60
Table 2.27: Polmekon's marketed polymer-based injectable products	60
Table 2.28: Suneva's marketed polymer-based injectable products	62
Table 2.29: ProCytech's marketed polymer-based injectable products	62
Table 2.30: Sanofi-Aventis' marketed polymer-based injectable products	63
Table 2.31: BioForm Medical's injectable ceramic-based products	65
Table 2.32: Stiefel Laboratories/GSK's injectable ceramic-based products	66
Table 3.33: Application of biomaterials for orthopedic applications	69
Table 4.34: Selected allosteric viscoaugmentation products in development	83
Table 4.35: Selected allosteric viscosupplementation products in development	86